Zogenix Submits IND for Second DosePro(R) Candidate Relday(TM)
Risperidone is one of the most widely prescribed medications used to treat the symptoms of schizophrenia in adults and teenagers 13 years of age and older. The global long-acting injectable antipsychotic market was approximately
If approved, Relday will be the first subcutaneous, needle-free antipsychotic product that allows for once-monthly dosing.
Hawley continued, "We anticipate having study results toward the end of the year which could position us to begin discussions regarding a rest-of-world development and commercialization partner. Should Relday receive
The DosePro system is a first-in-class, easy-to-use drug delivery system that includes a pre-filled, single dose of liquid drug, and is administered subcutaneously, without a needle. The platform is currently used by
For additional information, please visit www.zogenix.com.
Forward Looking Statements
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and
SUMAVEL®, DosePro®, ReldayTM and ZohydroTM are trademarks of
SABER® is a trademark of
CONTACT: Investor Contact Zack Kubow|
The Ruth Group646.536.7020 | email@example.com Media Contact The Ruth Group Victoria Aguiar646.536.7013 | firstname.lastname@example.org